A review of GM-CSF therapy in sepsis

Medicine (United States)

Volumn 94, Issue 50, 2015, Pages

  Mathias, Brittany ^a   Szpila, Benjamin E ^a   Moore, Frederick A ^a   Efron, Philip A ^a   Moldawer, Lyle L ^a  

^a UNIVERSITY OF FLORIDA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HLA DR ANTIGEN; IMMUNOMODULATING AGENT; AUTACOID; HLA ANTIGEN; LYMPHOCYTE ANTIGEN RECEPTOR;

ADAPTIVE IMMUNITY; ARTICLE; ARTIFICIAL VENTILATION; BONE MARROW SUPPRESSION; CLINICAL TRIAL (TOPIC); DEATH; DISABILITY; DISEASE SEVERITY; DRUG EFFECT; DRUG MECHANISM; ECONOMIC ASPECT; HEALTH CARE COST; HEALTH CARE UTILIZATION; HOSPITALIZATION; HUMAN; IMMUNE DEFICIENCY; IMMUNE SYSTEM; IMMUNOCOMPETENT CELL; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; INFLAMMATION; INTENSIVE CARE; LENGTH OF STAY; LEUKOCYTE COUNT; LEUKOCYTE FUNCTION; LUNG PROTECTION; MORBIDITY; MORTALITY; MULTIPLE ORGAN FAILURE; NEUTROPENIA; NONHUMAN; PRIORITY JOURNAL; PROPHYLAXIS; PROTECTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); SECONDARY INFECTION; SEPSIS; SURVIVAL; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; ADULT; AGED; ANIMAL; CRITICAL ILLNESS; IMMUNOLOGY; META ANALYSIS; METABOLISM; MOUSE; NEWBORN; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANIMALS; BIOMARKERS; CRITICAL ILLNESS; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HLA ANTIGENS; HUMANS; INFANT, NEWBORN; INFLAMMATION MEDIATORS; MICE; RECEPTORS, ANTIGEN; SEPSIS; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME;

EID: 84952673419     PISSN: 00257974     EISSN: 15365964     Source Type: Journal    
DOI: 10.1097/MD.0000000000002044     Document Type: Article

References (106)

1. Angus DC, Linde-Zwirble WT, Lidicker J, et al. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Critl Care Med. 2001;29:1303-1310.
2. Angus DC, Pereira CA, Silva E. Epidemiology of severe sepsis around the world. Endocr Metab Immune Disord Drug Targets. 2006;6:207-212.
3. Brooks SE, Mukherjee K, Gunter OL, et al. Do models incorporating comorbidities outperform those incorporating vital signs and injury pattern for predicting mortality in geriatric trauma? J Am Coll Surg. 2014;219:1020-1027.
4. Levy MM, Dellinger RP, Townsend SR, et al. The Surviving Sepsis Campaign: results of an international guideline-based performance improvement program targeting severe sepsis. Crit Care Med. 2010;38:367-374.
5. Cohen J, Opal S, Calandra T. Sepsis studies need new direction. Lancet Infect Dis. 2012;12:503-505.
6. Alberti C, Brun-Buisson C, Burchardi H, et al. Epidemiology of sepsis and infection in ICU patients from an international multicentre cohort study. Intensive Care Med. 2002;28:108-121.
7. Munford RS, Pugin J. Normal responses to injury prevent systemic inflammation and can be immunosuppressive. Am J Respir Crit Care Med. 2001;163:316-321.
8. Martin GS, Mannino DM, Eaton S, et al. The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med. 2003;348:1546-1554.
9. Annane D, Aegerter P, Jars-Guincestre MC, et al. Current epidemiology of septic shock: the CUB-Rea Network. Am J Respir Crit Care Med. 2003;168:165-172.
10. Cohen J. The immunopathogenesis of sepsis. Nature. 2002;420:885-891.
11. Monneret G, Venet F, Pachot A, et al. Monitoring immune dysfunctions in the septic patient: a new skin for the old ceremony. Mol Med. 2008;14:64-78.
12. Schefold JC, Hasper D, Volk HD, et al. Sepsis: time has come to focus on the later stages. Med Hypotheses. 2008;71:203-208.
13. Landelle C, Lepape A, Voirin N, et al. Low monocyte human leukocyte antigen-DR is independently associated with nosocomial infections after septic shock. Intensive Care Med. 2010;36:1859-1866.
14. Volk HD, Reinke P, Docke WD. Clinical aspects: from systemic inflammation to 'immunoparalysis'. Chem Immunol. 2000;74:162-177.
15. Annane D, Bellissant E, Cavaillon JM. Septic shock. Lancet. 2005;365:63-78.
16. Marchant A, Alegre ML, Hakim A, et al. Clinical and biological significance of interleukin-10 plasma levels in patients with septic shock. J Clin Immunol. 1995;15:266-273.
17. Yong KL, Rowles PM, Patterson KG, et al. Granulocyte-macrophage colony-stimulating factor induces neutrophil adhesion to pulmonary vascular endothelium in vivo: role of beta 2 integrins. Blood. 1992;80:1565-1575.
18. Meisel C, Schefold JC, Pschowski R, et al. Granulocyte-macrophage colony-stimulating factor to reverse sepsis-associated immunosuppression: a double-blind, randomized, placebo-controlled multicenter trial. Am J Respir Crit Care Med. 2009;180:640-648.
19. Heidecke CD, Weighardt H, Hensler T, et al. Immune paralysis of T-lymphocytes and monocytes in postoperative abdominal sepsis. Correlation of immune function with survival. Chirurg. 2000;71:159-165.
20. Bleiberg I, Riklis I, Fabian I. Enhanced resistance of bone marrow transplanted mice to bacterial infection induced by recombinant granulocyte-macrophage colony-stimulating factor. Blood. 1990;75:1262-1266.
21. Schefold JC. Measurement of monocytic HLA-DR (mHLA-DR) expression in patients with severe sepsis and septic shock: assessment of immune organ failure. Intensive Care Med. 2010;36:1810-1812.
22. Orozco H, Arch J, Medina-Franco H, et al. Molgramostim (GM-CSF) associated with antibiotic treatment in nontraumatic abdominal sepsis: a randomized, double-blind, placebo-controlled clinical trial. Arch Surg. 2006;141:150-153.
23. Schwiebert LM, Schleimer RP, Radka SF, et al. Modulation of MHC class II expression in human cells by dexamethasone. Cell Immunol. 1995;165:12-19.
24. Reith W, LeibundGut-Landmann S, Waldburger JM. Regulation of MHC class II gene expression by the class II transactivator. Nat Rev Immunol. 2005;5:793-806.
25. Vanzant EL, Lopez CM, Ozrazgat-Baslanti T, et al. Persistent inflammation, immunosuppression, and catabolism syndrome after severe blunt trauma. J Trauma Acute Care Surg. 2014;76:21-29.
26. Gentile LF, Cuenca AG, Efron PA, et al. Persistent inflammation and immunosuppression: a common syndrome and new horizon for surgical intensive care. J Trauma Acute Care Surg. 2012;72:1491-1501.
27. Docke WD, Randow F, Syrbe U, et al. Monocyte deactivation in septic patients: restoration by IFN-gamma treatment. Nat Med. 1997;3:678-681.
28. Schefold JC, von Haehling S, Corsepius M, et al. A novel selective extracorporeal intervention in sepsis: immunoadsorption of endotoxin, interleukin 6, and complement-activating product 5a. Shock. 2007;28:418-425.
29. Le Tulzo Y, Pangault C, Amiot L, et al. Monocyte human leukocyte antigen-DR transcriptional downregulation by cortisol during septic shock. Am J Respir Crit Care Med. 2004;169:1144-1151.
30. Austin OM, Redmond HP, Watson WG, et al. The beneficial effects of immunostimulation in posttraumatic sepsis. J Surg Res. 1995;59:446-449.
31. Hoesel LM, Gao H, Ward PA. New insights into cellular mechanisms during sepsis. Immunol Res. 2006;34:133-141.
32. Serafino A, Pierimarchi P, Pica F, et al. Thymosin alpha1 as a stimulatory agent of innate cell-mediated immune response. Ann N Y Acad Sci. 2012;1270:13-20.
33. Hotchkiss RS, Moldawer LL. Parallels between cancer and infectious disease. N Engl J Med. 2014;371:380-383.
34. Hamilton JA. Colony-stimulating factors in inflammation and autoimmunity. Nat Rev Immunol. 2008;8:533-544.
35. Frenck RW, Sarman G, Harper TE, et al. The ability of recombinant murine granulocyte-macrophage colony-stimulating factor to protect neonatal rats from septic death due to Staphylococcus aureus. J Infect Dis. 1990;162:109-114.
36. Basta PV, Moore TL, Yokota S, et al. A beta-adrenergic agonist modulates DR alpha gene transcription via enhanced cAMP levels in a glioblastoma multiforme line. J Immunol. 1989;142:2895-2901.
37. Moore KW, de Waal Malefyt R, Coffman RL, et al. Interleukin-10 and the interleukin-10 receptor. Annu Rev Immunol. 2001;19:683-765.
38. Presneill JJ, Harris T, Stewart AG, et al. A randomized phase II trial of granulocyte-macrophage colony-stimulating factor therapy in severe sepsis with respiratory dysfunction. Am J Respir Crit Care Med. 2002;166:138-143.
39. Bone RC, Grodzin CJ, Balk RA. Sepsis: a new hypothesis for pathogenesis of the disease process. Chest. 1997;112:235-243.
40. Hotchkiss RS, Coopersmith CM, McDunn JE, et al. The sepsis seesaw: tilting toward immunosuppression. Nat Med. 2009;15:496-497.
41. Hotchkiss RS, Karl IE. The pathophysiology and treatment of sepsis. N Engl J Med. 2003;348:138-150.
42. Monneret G, Debard AL, Venet F, et al. Marked elevation of human circulating CD4+CD25+ regulatory T cells in sepsisinduced immunoparalysis. Crit Care Med. 2003;31:2068-2071.
43. Bone RC. Toward a theory regarding the pathogenesis of the systemic inflammatory response syndrome: what we do and do not know about cytokine regulation. Crit Care Med. 1996;241:163-172.
44. Wiersinga WJ. Current insights in sepsis: from pathogenesis to new treatment targets. Curr Opin Crit Care. 2011;17:480-486.
45. Osuchowski MF, Welch K, Siddiqui J, et al. Circulating cytokine/inhibitor profiles reshape the understanding of the SIRS/CARS continuum in sepsis and predict mortality. J Immunol. 2006;177:1967-1974.
46. Cuenca AG, Delano MJ, Kelly-Scumpia KM, et al. A paradoxical role for myeloid-derived suppressor cells in sepsis and trauma. Mol Med. 2011;17:281-292.
47. Wolk K, Docke W, von Baehr V, et al. Comparison of monocyte functions after LPS- or IL-10-induced reorientation: importance in clinical immunoparalysis. Pathobiology. 1999;67:253-256.
48. Fumeaux T, Pugin J. Role of interleukin-10 in the intracellular sequestration of human leukocyte antigen-DR in monocytes during septic shock. Am J Respir Crit Care Med. 2002;166:1475-1482.
49. Hotchkiss RS, Monneret G, Payen D. Immunosuppression in sepsis: a novel understanding of the disorder and a new therapeutic approach. Lancet Infect Dis. 2013;13:260-268.
50. Wang H, Ma S. The cytokine storm and factors determining the sequence and severity of organ dysfunction in multiple organ dysfunction syndrome. Am J Emerg Med. 2008;26:711-715.
51. Gennari R, Alexander JW, Gianotti L, et al. Granulocyte macrophage colony-stimulating factor improves survival in two models of gut-derived sepsis by improving gut barrier function and modulating bacterial clearance. Ann Surg. 1994;220:68-76.
52. Bermudez LE, Martinelli JC, Gascon R, et al. Protection against gram-negative bacteremia in neutropenic mice with recombinant granulocyte-macrophage colony-stimulating factor. Cytokine. 1990;2:287-293.
53. Monneret G, Venet F. A rapidly progressing lymphocyte exhaustion after severe sepsis. Crit Care. 2012;16:140.
54. +) CD127 ((-)) contribute to lymphocyte anergy in septic shock patients. Intensive Care Med. 2009;35:678-686.
55. Belikova I, Lukaszewicz AC, Faivre V, et al. Oxygen consumption of human peripheral blood mononuclear cells in severe human sepsis. Crit Care Med. 2007;35:2702-2708.
56. Carson WF, Cavassani KA, Dou Y, et al. Epigenetic regulation of immune cell functions during post-septic immunosuppression. Epigenetics. 2011;6:273-283.
57. Gabrilovich DI, Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol. 2009;9:162-174.
58. LeVine AM, Reed JA, Kurak KE, et al. GM-CSF-deficient mice are susceptible to pulmonary group B streptococcal infection. J Clin Invest. 1999;103:563-569.
59. Lukaszewicz AC, Grienay M, Resche-Rigon M, et al. Monocytic HLA-DR expression in intensive care patients: interest for prognosis and secondary infection prediction. Crit Care Med. 2009;37:2746-2752.
60. Dellinger RP, Levy MM, Carlet JM, et al. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008. Intensive Care Med. 2008;34:17-60.
61. Kollef KE, Schramm GE, Wills AR, et al. Predictors of 30-day mortality and hospital costs in patients with ventilator-associated pneumonia attributed to potentially antibiotic-resistant gram-negative bacteria. Chest. 2008;134:281-287.
62. Otto GP, Sossdorf M, Claus RA, et al. The late phase of sepsis is characterized by an increased microbiological burden and death rate. Crit Care. 2011;15:R183.
63. Monneret G, Venet F, Kullberg BJ, et al. ICU-acquired immunosuppression and the risk for secondary fungal infections. Med Mycol. 2011;49(Suppl 1):S17-S23.
64. Heininger A, Haeberle H, Fischer I, et al. Cytomegalovirus reactivation and associated outcome of critically ill patients with severe sepsis. Crit Care. 2011;15:R77.
65. Osuchowski MF, Welch K, Yang H, et al. Chronic sepsis mortality characterized by an individualized inflammatory response. J Immunol. 2007;179:623-630.
66. Hotchkiss RS, Monneret G, Payen D. Sepsis-induced immunosuppression: from cellular dysfunctions to immunotherapy. Nat Rev Immunol. 2013;13:862-874.
67. Monneret G, Lepape A, Voirin N, et al. Persisting low monocyte human leukocyte antigen-DR expression predicts mortality in septic shock. Intensive Care Med. 2006;32:1175-1183.
68. Monneret G, Venet F, Meisel C, et al. Assessment of monocytic HLA-DR expression in ICU patients: analytical issues for multicentric flow cytometry studies. Crit Care. 2010;14:432.
69. Burgess AW, Metcalf D. The nature and action of granulocytemacrophage colony stimulating factors. Blood. 1980;56:947-958.
70. Fleetwood AJ, Cook AD, Hamilton JA. Functions of granulocytemacrophage colony-stimulating factor. Crit Rev Immunol. 2005;25:405-428.
71. Stanley E, Lieschke GJ, Grail D, et al. Granulocyte/macrophage colony-stimulating factor-deficient mice show no major perturbation of hematopoiesis but develop a characteristic pulmonary pathology. Proc Natl Acad Sci U S A. 1994;91:5592-5596.
72. Brissette WH, Baker DA, Stam EJ, et al. GM-CSF rapidly primes mice for enhanced cytokine production in response to LPS and TNF. Cytokine. 1995;7:291-295.
73. Hamilton JA. Colony stimulating factors, cytokines and monocytemacrophages: some controversies. Immunol today. 1993;14:18-24.
74. Stephens DP, Fisher DA, Currie BJ. An audit of the use of granulocyte colony-stimulating factor in septic shock. Intern Med J. 2002;32:143-148.
75. Wing EJ, Magee DM, Whiteside TL, et al. Recombinant human granulocyte/macrophage colony-stimulating factor enhances monocyte cytotoxicity and secretion of tumor necrosis factor alpha and interferon in cancer patients. Blood. 1989;73:643-646.
76. Stanley E, Lieschke GJ, Grail D, et al. Granulocyte/macrophage colony-stimulating factor-deficient mice show no major perturbation of hematopoiesis but develop a characteristic pulmonary pathology. Proc Natl Acad Sci U S A. 1994;91:5592-5596.
77. Paine 3rd R, Morris SB, Jin H, et al. Impaired functional activity of alveolar macrophages from GM-CSF-deficient mice. Am J Physiol Lung Cell Mol Physiol. 2001;281:L1210-1218.
78. Selgas R, Fernandez de Castro M, Jimenez C, et al. Immunomodulation of peritoneal macrophages by granulocyte-macrophage colony-stimulating factor in humans. Kidney Int. 1996;50:2070-2078.
79. Wada H, Noguchi Y, Marino MW, et al. T cell functions in granulocyte/macrophage colony-stimulating factor deficient mice. Proc Natl Acad Sci U S A. 1997;94:12557-12561.
80. McQualter JL, Darwiche R, Ewing C, et al. Granulocyte macrophage colony-stimulating factor: a new putative therapeutic target in multiple sclerosis. J Exp Med. 2001;194:873-882.
81. Lang RA, Metcalf D, Cuthbertson RA, et al. Transgenic mice expressing a hemopoietic growth factor gene (GM-CSF) develop accumulations of macrophages, blindness, and a fatal syndrome of tissue damage. Cell. 1987;51:675-686.
82. Elliott MJ, Faulkner-Jones BE, Stanton H, et al. Plasminogen activator in granulocyte-macrophage-CSF transgenic mice. J Immunol. 1992;149:3678-3681.
83. Stanley ER, Berg KL, Einstein DB, et al. Biology and action of colony: stimulating factor-1. Mol Reprod Dev. 1997;46:4-10.
84. Whetton AD, Dexter TM. Myeloid haemopoietic growth factors. Biochimica Biophys Acta. 1989;989:111-132.
85. Bresnihan B, Gerlag DM, Rooney T, et al. Synovial macrophages as a biomarker of response to therapeutic intervention in rheumatoid arthritis: standardization and consistency across centers. J Rheumatol. 2007;34:620-622.
86. Verreck FA, de Boer T, Langenberg DM, et al. Human IL-23-producing type 1 macrophages promote but IL-10-producing type 2 macrophages subvert immunity to (myco) bacteria. Proc Natl Acad Sci U S A. 2004;101:4560-4565.
87. Zucali JR, Dinarello CA, Oblon DJ, et al. Interleukin 1 stimulates fibroblasts to produce granulocyte-macrophage colony-stimulating activity and prostaglandin E2. J Clin Invest. 1986;77:1857-1863.
88. Bagby GC Jr, Dinarello CA, Wallace P, et al. Interleukin 1 stimulates granulocyte macrophage colony-stimulating activity release by vascular endothelial cells. J Clin Invest. 1986;78:1316-1323.
89. Filonzi EL, Zoellner H, Stanton H, et al. Cytokine regulation of granulocyte-macrophage colony stimulating factor and macrophage colony-stimulating factor production in human arterial smooth muscle cells. Atherosclerosis. 1993;99:241-252.
90. Hamilton JA. Rheumatoid arthritis: opposing actions of haemopoietic growth factors and slow-acting anti-rheumatic drugs. Lancet. 1993;342:536-539.
91. Bender A, Amann U, Jager R, et al. Effect of granulocyte/macrophage colony-stimulating factor on human monocytes infected with influenza A virus. Enhancement of virus replication, cytokine release, and cytotoxicity. J Immunol. 1993;151:5416-5424.
92. Shindo J, Ishibashi T, Yokoyama K, et al. Granulocyte-macrophage colony-stimulating factor prevents the progression of atherosclerosis via changes in the cellular and extracellular composition of atherosclerotic lesions in watanabe heritable hyperlipidemic rabbits. Circulation. 1999;99:2150-2156.
93. Xing Z, Ohkawara Y, Jordana M, et al. Transfer of granulocytemacrophage colony-stimulating factor gene to rat lung induces eosinophilia, monocytosis, and fibrotic reactions. J Clin Invest. 1996;97:1102-1110.
94. Piguet PF, Grau GE, de Kossodo S. Role of granulocytemacrophage colony-stimulating factor in pulmonary fibrosis induced in mice by bleomycin. Exp Lung Res. 1993;19:579-587.
95. Toda H, Murata A, Oka Y, et al. Effect of granulocyte-macrophage colony-stimulating factor on sepsis-induced organ injury in rats. Blood. 1994;83:2893-2898.
96. Rosenbloom AJ, Linden PK, Dorrance A, et al. Effect of granulocyte-monocyte colony-stimulating factor therapy on leukocyte function and clearance of serious infection in nonneutropenic patients. Chest. 2005;127:2139-2150.
97. Bo L, Wang F, Zhu J, et al. Granulocyte-colony stimulating factor (G-CSF) and granulocyte-macrophage colony stimulating factor (GM-CSF) for sepsis: a meta-analysis. Crit Care. 2011;15:R58.
98. Carlet J, Cohen J, Calandra T, et al. Sepsis: time to reconsider the concept. Crit Care Med. 2008;36:964-966.
99. Pachot A, Monneret G, Brion A, et al. Messenger RNA expression of major histocompatibility complex class II genes in whole blood from septic shock patients. Crit Care Med. 2005;33:31-38.
100. Perry SE, Mostafa SM, Wenstone R, et al. Is low monocyte HLA-DR expression helpful to predict outcome in severe sepsis? Intensive Care Med. 2003;29:1245-1252.
101. Gentile LF, Nacionales DC, Lopez MC, et al. Protective immunity and defects in the neonatal and elderly immune response to sepsis. J Immunol. 2014;192:3156-3165.
102. Nacionales DC, Gentile LF, Vanzant E, et al. Aged mice are unable to mount an effective myeloid response to sepsis. J Immunol. 2014;192:612-622.
103. Carr R, Modi N, Dore C. G-CSF and GM-CSF for treating or preventing neonatal infections. Cochrane Database Syst Rev. 2003: CD003066.
104. Bernstein HM, Pollock BH, Calhoun DA, et al. Administration of recombinant granulocyte colony-stimulating factor to neonates with septicemia: a meta-analysis. J Pediatr. 2001;1386:917-920.
105. van der Poll T, Opal SM. Host-pathogen interactions in sepsis. Lancet Infect Dis. 2008;8:32-43.
106. Ward PA, Bosmann M. A historical perspective on sepsis. Am J Pathol. 2012;181:2-7.